CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies


Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).


The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.


CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos

Video Series

e-SPACE Cardio-Renal-Metabolic 2023

Fausto J Pinto, John Spertus, , et al

Watch time: 16h 19m 46s (19 videos)


ACC 23 Late-breaking Discussion: The COORDINATE-Diabetes Trial

Harriette Van Spall, Neha Pagidipati, Christopher B Granger, et al

Watch time: 17m 32s


Radcliffe & CardioNerds @AHA22: The PROMINENT Trial

Aruna D Pradhan, Gurleen Kaur,

Watch time: 14m 20s


AHA 22: BT001 PIVOTAL: nCBT in Pts with Type II Diabetes

Marc P Bonaca,

Watch time: 7m 23s


EASD 22: Efficacy of Ertugliflozin HHF Across the Spectrum of Pre-Trial EF

Ambarish Pandey,

Watch time: 3m 5s


ESC 22: ASCEND: Aspirin and Omega-3 Fatty Acids in Preventing Heart Failure

Michelle Goonasekera,

Watch time: 5m 34s
Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes

US Cardiology Review 2019;13(1):49–53

Diabetic Cardiomyopathy: Five Major Questions with Simple Answers

US Cardiology Review 2019;13(1):46–8

Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift

US Cardiology Review 2018;12(1):46–50.

Novel Pharmacologic Treatments for Cardiovascular Disease: A Practical Update

US Cardiology Review 2017;11(2):98–104.

Identification of Patients at Risk of Stroke From Atrial Fibrillation

US Cardiology Review 2016;10(2):60–4

What the Cardiologist Needs to Know About Medications for Type 2 Diabetes

US Cardiology Review 2016;10(2):54–9


US Cardiology, 2006;3(1):11

Detection of Silent Coronary Artery Disease in Asymptomatic Patients with Type 2 Diabetes Mellitus

US Cardiology 2005;2(1):44–6

Cardiovascular Risk Factors in Metabolic Syndrome—Impact of Insulin Resistance on Lipids, Hypertension, and the Development of Diabetes and Cardiac Events

US Cardiology 2005;2(1):35–8

The Cardiologist's Role in the Management of Type 2 Diabetes - A Review

US Cardiology 2012;9(1):26-9

Treatment of Type 2 Diabetes with a Combination of Two Insulin Sensitizers — Increased Efficacy and Fewer Side-effects

US Cardiology 2004;1(1):29–33

High-density Lipoprotein Cholesterol — The Next Battle Front in the Fight Against Heart Disease

US Cardiology 2004;1(1):34–8

Angiotensin-receptor Blocker Therapy—Chronic Kidney Disease and Diabetes

US Cardiology 2006;3(2):32–4

Treating the Common Dyslipidemia in Patients with Type 2 Diabetes—The Effects of Fenofibrate on Cardiovascular Disease Risk

US Cardiology 2006;3(1):1–5

Management of Cholesterol in Diabetes - A Review

US Cardiology 2010;7(2):20–4

Management of the Asymptomatic Diabetic Patient with Evidence of Ischemia

US Cardiology 2010; 7(1):76–80

Cardiovascular Risk in Type 2 Diabetes - Reflecting on the ADVANCE Study

US Cardiology 2009;6(2):46–50

Minimizing Cardiovascular Complications by Early Diagnosis of Diabetes

US Cardiology 2007;4(1):35–6

Metabolic Syndrome - A Common and Dangerous Health Problem

US Cardiology 2007;4(1):37–40

Treatment of Hypertension in Patients with Chronic Kidney Disease

US Cardiology 2009;6(2):54–8